Pure Febuxostat Powder

Febuxostat powder is an oral, highly selective xanthine oxidase inhibitor in pure crystalline powder pharmaceutical raw material form. It is a urate-lowering agent specially developed for hyperuricemia and gout treatment, with chemical selectivity far superior to traditional allopurinol.

Selectively inhibits xanthine oxidase, the key catalytic enzyme in the human purine metabolic pathway.

Blocks the conversion of hypoxanthine and xanthine into uric acid, drastically reducing endogenous uric acid production in the body.

Effectively lowers serum uric acid concentration to reach the target therapeutic level.

Therapeutic Efficacy & Clinical Indications

Long-term management of chronic hyperuricemia Stably controls persistently elevated blood uric acid, avoids sustained high urate accumulation in body fluid.

Prevention and treatment of gout

Reduces acute gout flare-ups by dissolving deposited monosodium urate crystals in joints and soft tissues.

Gradually shrinks tophi (gout nodules) formed by long-term uric acid deposition under skin and around joints.

Relieves joint swelling, redness, tenderness and limited mobility caused by crystal inflammation.

Adjuvant improvement of gout-related complications Lowers the risk of uric acid kidney stones, renal tubular damage and gouty nephropathy induced by hyperuricemia.

Advantages of Febuxostat Powder

Strong target selectivity: Rarely interferes with other purine metabolism enzymes, leading to fewer systemic adverse reactions.

Efficient uric acid reduction: Works at low dosages and achieves ideal serum urate levels faster than allopurinol for most patients.

Mild renal metabolism burden: Suitable for hyperuricemia patients with mild to moderate renal impairment who cannot tolerate allopurinol.

Prescription dermatological pharmaceutical raw material (acne treatment cream/gel, scalp anti-hair loss topical preparations)

High-efficiency functional cosmetic raw material for oil-control, anti-acne and anti-hair-loss serums, lotions and essences

Laboratory research reagent for androgen receptor pharmacology and dermatology studies

1. Common Side Effects

These mild reactions usually appear at the initial stage of medication and may ease as the body adapts:

Liver function abnormalities: Elevated liver transaminases (ALT/AST), occasional mild hepatic discomfort. Regular liver function tests are required during long-term use.

Joint-related reactions: Temporary gout flares (joint pain, swelling, redness). When febuxostat rapidly reduces blood uric acid, deposited urate crystals dissolve and trigger acute inflammatory attacks.

Digestive discomfort: Nausea, diarrhea, stomach ache, flatulence, loss of appetite.

Skin reactions: Mild rash, itching, flushing of the skin.

Fatigue, dizziness and headache.

2. Less Common Side Effects

Urinary system issues: Increased urine frequency, minor renal function index fluctuations, urinary stones.

Cardiovascular symptoms: Palpitations, chest tightness, slight blood pressure changes.

Musculoskeletal discomfort: Muscle soreness, back pain.

Abnormal blood indicators: Minor decreases in white blood cells or platelet counts.

3. Severe Rare Adverse Reactions (Seek immediate medical help once occurred)

Severe hypersensitivity: Severe widespread rash, blisters, exfoliative dermatitis, swelling of the face/lips/throat, difficulty breathing or swallowing.

Severe liver injury: Persistent jaundice (yellow skin and sclera), dark urine, severe right upper abdominal pain.

Serious cardiovascular events: Myocardial infarction, angina pectoris, stroke; patients with a history of heart disease need strict medical monitoring.

Severe renal damage: Sharp decline in urine output, obvious edema of limbs, persistent high creatinine.

Severe blood disorders: Unusual bruising, spontaneous bleeding, persistent fever caused by abnormal blood cell counts.

1. Slow Dose Titration to Avoid Acute Gout Flares

Sudden sharp drops in serum uric acid trigger crystal dissolution and joint inflammation, the most frequent side effect.

Start with a low initial dose as instructed by physicians, instead of taking full therapeutic dosage directly.

Gradually raise the dose every 2–4 weeks based on regular blood uric acid test results.

Combine short-term anti-inflammatory drugs (colchicine or NSAIDs) within the first 3–6 months of administration to prevent sudden gout attacks.

Do not discontinue febuxostat abruptly; sudden withdrawal causes uric acid rebound and severe gout flares.

2. Protect Liver Function to Alleviate Hepatic Side Effects

Elevated liver enzymes are one of the common adverse reactions.

Complete liver function tests before treatment and recheck liver indicators every 1–3 months during long-term use.

Avoid alcohol, high-fat fried food and liver-damaging supplements/medicines simultaneously.

Take the powder after meals to lower liver metabolic burden.

Stop medication and seek medical care immediately if jaundice, dark urine or persistent upper abdominal pain appears.

3. Relieve Gastrointestinal Discomfort

Nausea, diarrhea and stomach ache can be relieved by adjusting administration habits:

Administer febuxostat powder with food or a full glass of warm water, never on an empty stomach.

Split the daily dose into two smaller intakes if severe stomach upset occurs.

Cut down purine-rich food, spicy and irritating food to reduce gastrointestinal stimulation.

4. Minimize Skin Allergic Reactions

Conduct a small-dose trial at the beginning; stop use and consult a doctor once mild rash or itching emerges.

Avoid taking other allergenic medicines or health products during the treatment period.

Refrain from hot water scouring or scratching affected skin areas if mild skin reactions occur.

5. Lower Cardiovascular Risks

Febuxostat carries slight cardiovascular risks for patients with underlying heart disease.

Patients with hypertension, coronary heart disease or a history of stroke must inform doctors before use for risk assessment.

Monitor blood pressure and heart rate regularly while taking the powder.

Maintain low-salt, low-oil diet and proper daily exercise to stabilize cardiovascular status.

Seek emergency treatment instantly if chest tightness, palpitations or chest pain happens.

6. Prevent Renal Side Effects

Maintain sufficient daily water intake (2000–3000 mL per day) to boost urate excretion and avoid kidney stone formation.

Limit high-purine seafood, animal offal and sugary drinks that increase renal metabolic load.

Periodically test renal function and urine routine, especially for patients with pre-existing mild renal impairment.

7. General Daily Lifestyle Adjustments

Avoid excessive fatigue, staying up late and heavy strenuous exercise which aggravate dizziness and fatigue.

Control weight steadily; rapid weight loss will trigger gout flares.

Do not combine febuxostat with other urate-lowering agents without professional medical guidance to prevent super low uric acid and aggravated adverse effects.

1. Initial biochemical effect (lowering blood uric acid)

Febuxostat begins to suppress xanthine oxidase rapidly after oral absorption.

A noticeable drop in serum uric acid can be detected within 24 hours after the first dose.

Stable uric acid reduction can be observed after continuous use for 3 to 7 days. Most patients reach obvious urate-lowering effects within one week of regular daily administration.

2. Time to reach target therapeutic uric acid level

The target for most gout patients is serum uric acid below 360 μmol/L (6 mg/dL).

For patients with mild hyperuricemia: It takes roughly 2 to 4 weeks at a standard dose to hit the target value.

For patients with severe hyperuricemia or large tophi: Dose titration is needed, so it may take 1 to 3 months to steadily maintain uric acid at the target range.

3. Time to improve clinical gout symptoms

(1) Prevention of acute gout attacks

Do not expect instant pain relief during an acute flare - febuxostat cannot ease existing joint inflammation right away. In the first 1–6 months of treatment, dissolved urate crystals easily trigger temporary gout flares. After continuous use for 6 months or longer, the frequency and severity of sudden joint swelling and pain will drop significantly as crystal deposits shrink.

(2) Dissolution of tophi (gout nodules)

Tophi are formed by long-term urate crystal accumulation under skin and around joints, which dissolve very slowly.

Small tophi: Visible shrinkage after 6–12 months of stable target uric acid control.

Large, hard tophi: May require 1–3 years of consistent medication to fully resolve.

Febuxostat is a long-term maintenance drug for hyperuricemia, not a fast-acting painkiller for acute gout. Anti-inflammatory or analgesic medicines are required separately to relieve sudden joint pain.

Even if blood uric acid falls to normal quickly, do not stop taking febuxostat arbitrarily, otherwise uric acid will rebound and gout attacks will recur.

Individual onset speed varies, affected by initial uric acid concentration, liver and kidney function, dosage, diet and drinking habits. Regular blood uric acid testing helps judge the actual efficacy.

Product list

Delivery Time:Around 3-5 workdays after your payment.

Package:1kg/aluminium foil bag;25Kgs in fiber-drums with two-plastic bags inside

Net Weight:25kgs/Drum/Gross Weight:28kgs/Drum

Drum Size & Volume:I.D.42cm × H52cm,0.08 m³/Drum

Storage:Stored in dry and cool place,keep away from strong light and heat.

Shelf Life:Two years when properly stored.

Hot Tags: pure febuxostat powder, China pure febuxostat powder manufacturers, suppliers, factory, 4 Aminobenzoic Acid for Skin, Berberine for Blood Sugar Support, Dihydroberberine Powder Supplier, Pramoxine HCl for Topical Use, Yohimbine Hydrochloride for Exercise Performance, Yohimbine Hydrochloride for Weight Management